Treatment of Wangiella (Exophiala) dermatitidis Infection
For confirmed Wangiella (Exophiala) dermatitidis infection, initiate voriconazole as primary antifungal therapy combined with surgical intervention when feasible, as this combination demonstrates superior outcomes compared to amphotericin B-based regimens.
Primary Treatment Approach
The evidence strongly supports voriconazole as the first-line antifungal agent for E. dermatitidis infections 1, 2, 3. Recent case reports consistently demonstrate better outcomes with voriconazole compared to amphotericin B formulations, particularly when combined with surgical management 1, 2.
Recommended Antifungal Regimen
- Voriconazole: 400 mg (6 mg/kg) IV twice daily for 2 doses, then 200 mg (3 mg/kg) twice daily
- Consider combination therapy with liposomal amphotericin B (3-5 mg/kg daily) for severe or disseminated disease, particularly prosthetic valve endocarditis 1
- Duration: Prolonged therapy is required, typically several months depending on infection site and clinical response 4
Site-Specific Considerations
Central Nervous System Infection
CNS involvement is the single most important predictor of mortality (OR = 35.432) 5. E. dermatitidis has significantly higher risk of CNS infection compared to other Exophiala species 5.
- Voriconazole is preferred due to excellent CSF penetration
- Consider combination with liposomal amphotericin B initially
- Surgical drainage may be necessary for focal lesions or abscesses
- Prolonged therapy (≥12 months) is essential
Bloodstream/Catheter-Associated Infections
E. dermatitidis shows 12.5-fold higher risk of bloodstream infection 5.
- Immediate central line removal is mandatory 3
- Voriconazole monotherapy may be sufficient after catheter removal
- Continue treatment for at least 2 weeks after blood culture clearance and symptom resolution
Prosthetic Valve Endocarditis
This represents the most severe manifestation with high mortality risk 1, 6.
- Early surgical valve replacement is critical 1, 6
- Dual antifungal therapy: voriconazole + liposomal amphotericin B
- Prolonged antifungal therapy (6-12 months minimum)
Ocular Infections
Amphotericin B-based regimens show poor outcomes for endophthalmitis 2.
- Voriconazole is strongly preferred (systemic ± intravitreal)
- Surgical intervention (vitrectomy or evisceration) often required
- Avoid corticosteroids, which worsen outcomes 2
Pulmonary Infections
E. dermatitidis has 44.8-fold higher risk of lung involvement 5.
- Voriconazole as primary therapy
- Surgical resection for localized disease when feasible
- Monitor for dissemination in immunocompromised patients
Cutaneous/Subcutaneous Infections
- Voriconazole or itraconazole (200 mg 2-3 times daily)
- Surgical debridement enhances outcomes 4
- Less aggressive therapy may suffice for localized superficial disease
Critical Pitfalls to Avoid
Do not rely on amphotericin B monotherapy: Recent evidence shows poor outcomes, particularly for endophthalmitis 2
Do not delay surgical intervention: Combined medical-surgical approach is essential for most deep-seated infections 4
Do not use echinocandins as monotherapy: Micafungin shows high MEC values (4 μg/mL) against E. dermatitidis 3, though combination with azoles may be considered
Do not underestimate treatment duration: These infections are chronic and recalcitrant, requiring prolonged therapy 4
Do not miss CNS involvement: Image the brain in immunocompromised patients with disseminated disease, as CNS infection dramatically increases mortality 5
Diagnostic Confirmation
While not treatment per se, rapid identification is crucial:
- Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)
- Internal transcribed spacer (ITS) sequencing
- Nanopore sequencing for rapid identification 1
Special Populations
Immunocompromised patients: More aggressive combination therapy with voriconazole + liposomal amphotericin B, with lower threshold for surgical intervention 4.
Prosthetic device infections: Device removal is non-negotiable for successful treatment 1, 6, 3.